A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)

[1]  S. Libutti,et al.  Cancer of the rectum , 2018 .

[2]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[3]  K. Yamashita,et al.  Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. , 2014, International journal of radiation oncology, biology, physics.

[4]  N. Petrelli,et al.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Conroy,et al.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Torsten Hothorn,et al.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.

[7]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Yamashita,et al.  A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. , 2011, International journal of radiation oncology, biology, physics.

[9]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[10]  J. Roh,et al.  Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Zampino,et al.  Rectal cancer. , 2009, Critical reviews in oncology/hematology.

[13]  M. Fukushima,et al.  S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. , 2006, Oncology reports.

[14]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[15]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jinnai Dennosuke,et al.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus , 1983 .

[17]  E. PeñaydelaPeña,et al.  [Cancer of the rectum]. , 1955, Revista de sanidad militar.

[18]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.